MedTrace Logo

The Effects of PXR Activation on Hepatic Fat Content

NCT02329405 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2017-11-01

No results posted yet for this study

Summary

This study investigates the effects of pregnane X receptor (PXR) activation on hepatic fat content in healthy volunteers. Rifampicin (an antibiotic and also an efficient PXR activator) and placebo will be given for a week to volunteers. Hepatic fat content is measured with magnetic resonance imaging and blood samples are collected at the end of each study arm. The investigators' hypothesis is that rifampicin causes accumulation of fat to the liver.

Conditions

  • Non-alcoholic Fatty Liver Disease

Interventions

DRUG

Rifampicin

DRUG

Placebo

Sponsors & Collaborators

  • Oulu University Hospital

    collaborator OTHER

  • University of Oulu

    lead OTHER

Principal Investigators

  • Janne Hukkanen, MD, PhD · Oulu University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2017-01-31
Completion
2017-01-31

Countries

  • Finland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02329405 on ClinicalTrials.gov